Google Alert - "Myeloproliferative neoplasms" OR "polycythemia vera" OR myelofibrosis OR "essential thrombocythemia" google.com

INCY Wins EC Approval for Label Expansion of Oncology Drug Zynyz

google.com·10w

PIM-1 Inhibition Offers a Novel Approach in Myelofibrosis

google.com·10w

Early-Stage PIM-1 Kinase Inhibitors Explored in Myelofibrosis

google.com·10w

Galecto Announces Name Change to Damora Therapeutics with Mission to Fundamentally ...

google.com·10w

Galecto changes name to Damora Therapeutics, shifts focus to blood disorders

google.com·10w

A Patient's Guide to Navigating Stage 3 Essential Thrombocythemia

google.com·10w

Norma Jean Neto Obituary - Fremont, CA (1937-2026)

google.com·10w

Acute Myocardial Infarction Managed with Thrombolysis in Polycythemia Vera Patient

google.com·10w

Sino Biopharma strikes $1.53bn deal with Sanofi for JAK/ROCK inhibitor

google.com·10w

Alnylam bets on Tenaya RNAi tech, and other licensing news

google.com·10w

OncLive Weekly News Quiz (3/6/2026): Brush Up on Regulatory Splashes in Myeloma, RCC, and PV

google.com·10w

Comparison of anxiety symptoms in patients with myeloproliferative neoplasms treated with ...

google.com·10w

The Intricate Dance Between Inflammation and Myeloproliferative Neoplasms

google.com·10w

Patient Engagement Predicts Self-Care Behaviors in Patients With Myeloproliferative Neoplasms

google.com·10w

The SENTRY Trial: Selinexor Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis

google.com·10w

Pharmacists on the Frontlines of Myelofibrosis Care: Addressing Symptom Burden ...

google.com·10w

Sanofi licenses rovadicitinib from Sino Biopharm in up to $1.5 billion deal

google.com·10w

Are You Familiar with Essential Thrombocythemia ?

google.com·10w

Sanofi gains access to first-in-class JAK inhibitor through $1.5bn licensing deal

google.com·11w

From essential thrombocythemia to polycythemia vera (ET-2-PV): rationale and design of a ...

google.com·11w

Log in to enable infinite scrolling